Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Roques

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.
British Journal of Cancer|September 16, 2021
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK auditAlexa Childs, Nekisa Zakeri, Yuk Ting Ma, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Journal of Medical Genetics|January 28, 2012
Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24Angela M Jones, Kimberley M Howarth, Lynn Martin, et al.
The New England Journal of Medicine|May 4, 2012
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancerUjjal Mallick, Clive Harmer, Beng Yap, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Lancet (London, England)|June 21, 2025
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trialUjjal Mallick, Kate Newbold, Matthew Beasley, et al.
JAMA Oncology|December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional EvaluationLennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.
British Journal of Cancer|September 16, 2021
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK auditAlexa Childs, Nekisa Zakeri, Yuk Ting Ma, et al.
BMC Cancer|October 8, 2016
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancerImran Petkar, Keith Rooney, Justin W G Roe, et al.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Journal of Medical Genetics|January 28, 2012
Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24Angela M Jones, Kimberley M Howarth, Lynn Martin, et al.
The New England Journal of Medicine|May 4, 2012
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancerUjjal Mallick, Clive Harmer, Beng Yap, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Lancet (London, England)|June 21, 2025
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trialUjjal Mallick, Kate Newbold, Matthew Beasley, et al.
JAMA Oncology|December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional EvaluationLennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Pageof 4